Tyler Wish, announced today that Dr. Pek Lum, CEO of Capella Bio (www.capellabio.com), has joined the company's Advisory Board.

PALO ALTO, CALIFORNIA, UNITED STATES, October 29, 2015 /EINPresswire.com/ -- (October 14, 2015, St. John’s, Newfoundland/Palo Alto, California) - Sequence Bio CEO, Dr. Tyler Wish, announced today that Dr. Pek Lum, CEO of Capella Bio (www.capellabio.com), has joined the company's Advisory Board. In this capacity, Dr. Lum will lend her expertise and insight gained at the highest levels of the life sciences industry.

Dr. Pek Lum is a renowned data scientist and systems biologist who has extensive experience with data driven drug discovery, software development and venture capital. She is currently the CEO of Capella Bio, a computational drug development company based in Palo Alto, CA. Dr. Lum currently holds advisory positions with organizations such as Bayes Impact and The Michael J. Fox Foundation for Parkinson's Research. Previously, Dr. Lum held senior executive and scientific positions at,Rosetta, Merck, iPierian and Ayasdi.

Dr. Tyler Wish notes the importance of this appointment to the Sequence Bio team, “I am very pleased to welcome Dr. Lum to the Advisory Board. She is recognized as a leader in the field of precision medicine and her expertise will make a meaningful impact to advancing patient care and enabling modern drug discovery. Our entire team is grateful for the opportunity to work with Dr. Lum.”

Today, in Palo Alto, Dr. Lum expressed her interest for joining the advisory board, “Sequence Bio is leading an important initiative that will advance the field of precision medicine. They have a unique opportunity and I’m excited to play a role to help with their success.”

Karen Moores
Sequence Bio
709-697-0734
email us here